{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T05:24:46Z","timestamp":1748237086541},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:00:00Z","timestamp":1576108800000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>The resistance to antimony-containing glucantime is a major obstacle to successful treatment, especially in endemic areas. Looking the molecular mechanisms involved in this drug resistance will help in choosing the best treatment. The aim of this study was to evaluate the expression of multidrug-resistance 1 (MDR1) and multidrug-resistance protein A (MRPA) genes in acute, chronic non-lupoid, and chronic lupoid forms of dry type cutaneous leishmaniasis (DTCL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>MDR1 gene was over-expressed as 14.4- and 1.56-folds in the chronic lupoid and acute forms compared with the chronic non-lupoid form, respectively. Results comparison showed P\u2009&lt;\u20090.05 between the chronic non-lupoid and acute groups, P\u2009&lt;\u20090.01 between acute and chronic lupoid groups, and P\u2009&lt;\u20090.001 between the chronic non-lupoid and chronic lupoid groups. MRPA gene was over-expressed as 266 and 17.7-fold in the chronic lupoid and chronic non-lupoid forms compared with the acute form, respectively. Statistical analysis showed P\u2009&lt;\u20090.01 between the chronic non-lupoid and chronic lupoid groups, P\u2009&lt;\u20090.05 between acute and chronic non-lupoid groups, and P\u2009&lt;\u20090.001 between the acute and chronic lupoid groups.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13104-019-4784-0","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T16:23:58Z","timestamp":1576167838000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of MDR1 and MRPA genes expression in different types of dry cutaneous leishmaniasis"],"prefix":"10.1186","volume":"12","author":[{"given":"Maryam","family":"Fekrisoofiabadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meisam","family":"Fekri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Moradabadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Vahidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morteza","family":"Khaleghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Ram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahriar","family":"Dabiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,12]]},"reference":[{"issue":"1","key":"4784_CR1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4103\/0972-9062.112532","volume":"50","author":"M Karami","year":"2013","unstructured":"Karami M, Doudi M, Setorki M. Assessing epidemiology of cutaneous leishmaniasis in Isfahan, Iran. J Vector Borne Dis. 2013;50(1):30.","journal-title":"J Vector Borne Dis"},{"issue":"3","key":"4784_CR2","first-page":"235","volume":"16","author":"S Talari","year":"2012","unstructured":"Talari S, Kazemi B, Hooshyar H, Alizadeh R, Arbabi M, Mousavi G, et al. Identification of mutation for drug resistance gene in cutaneous leishmaniasis. Feyz J Kashan Univ Med Sci. 2012;16(3):235\u20139.","journal-title":"Feyz J Kashan Univ Med Sci"},{"issue":"4","key":"4784_CR3","first-page":"238","volume":"14","author":"SS Meymandi","year":"2011","unstructured":"Meymandi SS, Javadi A, Dabiri S, Nadji M. Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy. Arch Iran Med. 2011;14(4):238.","journal-title":"Arch Iran Med."},{"key":"4784_CR4","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-202x.2001.00038.x","author":"CM Choi","year":"2001","unstructured":"Choi CM, Lerner EA. Leishmaniasis as an emerging infection. J Invest Derm Symp Proc. 2001. https:\/\/doi.org\/10.1046\/j.0022-202x.2001.00038.x","journal-title":"J Invest Derm Symp Proc"},{"issue":"1","key":"4784_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaad.2008.09.036","volume":"60","author":"C Garcia","year":"2009","unstructured":"Garcia C, Poletti E, Crowson AN. Basosquamous carcinoma. J Am Acad Dermatol. 2009;60(1):137\u201343.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"4784_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0738-081X(99)00047-4","volume":"17","author":"SM Salman","year":"1999","unstructured":"Salman SM, Rubeiz NG, Kibbi A-G. Cutaneous leishmaniasis: clinical features and diagnosis. Clin Dermatol. 1999;17(3):291\u20136.","journal-title":"Clin Dermatol"},{"issue":"11","key":"4784_CR7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/j.1365-4632.2004.02359.x","volume":"43","author":"S Meymandi","year":"2004","unstructured":"Meymandi S, Dabiri S, Dabiri D, Crawford RI, Kharazmi A. A quantitative study of epidermal Langerhans cells in cutaneous leishmaniasis caused by Leishmania tropica. Int J Dermatol. 2004;43(11):819\u201323.","journal-title":"Int J Dermatol"},{"key":"4784_CR8","first-page":"538","volume":"3","author":"T Garnier","year":"2002","unstructured":"Garnier T, Croft SL. Topical treatment for cutaneous leishmaniasis. Curr Opin Investig Drugs. 2002;3:538\u201344.","journal-title":"Curr Opin Investig Drugs"},{"issue":"1","key":"4784_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1046\/j.0011-9059.2001.01396.x","volume":"41","author":"MS Gurel","year":"2002","unstructured":"Gurel MS, Ulukanligil M, Ozbilge H. Cutaneous leishmaniasis in Sanliurfa: epidemiologic and clinical features of the last four years (1997\u20132000). Int J Dermatol. 2002;41(1):32\u20137.","journal-title":"Int J Dermatol"},{"issue":"11","key":"4784_CR10","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1046\/j.1365-4362.1998.00478.x","volume":"37","author":"MP Oliveira-Neto","year":"1998","unstructured":"Oliveira-Neto MP, Mattos M, da Silva C, de Souza F, Fernandes O, Pirmez C. Leishmaniasis recidiva cutis in new world cutaneous leishmaniasis. Int J Dermatol. 1998;37(11):846\u20139.","journal-title":"Int J Dermatol"},{"issue":"4","key":"4784_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/00034983.1980.11687365","volume":"74","author":"S Ardehali","year":"1980","unstructured":"Ardehali S, Sodeiphy M, Haghighi P, Rezai H, Vollum D. Studies on chronic (lupoid) leishmaniasis. Ann Trop Med Parasitol. 1980;74(4):439\u201345.","journal-title":"Ann Trop Med Parasitol"},{"issue":"1","key":"4784_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1186\/s13104-019-4666-5","volume":"12","author":"MA Fekri","year":"2019","unstructured":"Fekri MA, Fekri ME, Moradabadi A, Vahidi R, Shamsi-Meymandi S, Dabiri D, Dabiri S. Ability of real-time PCR for differential diagnosis of various forms of cutaneous leishmaniasis: a comparative study with histopathology. BMC Research Notes. 2019;12(1):615.","journal-title":"BMC Research Notes."},{"issue":"11","key":"4784_CR13","first-page":"79","volume":"19","author":"AL Moradabadi","year":"2017","unstructured":"Moradabadi AL, Farsinejad A, Fekri SM. Fast method for diagnosis of leishmania by PCR and FLASH PCR. J Arak Univ Med Sci. 2017;19(11):79\u201386.","journal-title":"J Arak Univ Med Sci."},{"issue":"7","key":"4784_CR14","first-page":"496","volume":"19","author":"S Dabiri","year":"2016","unstructured":"Dabiri S, Amirpoor S. Design and validation of real-time PCR: quantitative diagnosis of common Leishmania species in Iran. Arch Iran Med. 2016;19(7):496.","journal-title":"Arch Iran Med."},{"issue":"3","key":"4784_CR15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1590\/S0365-05962011000300012","volume":"86","author":"OLS Almeida","year":"2011","unstructured":"Almeida OLS, Santos JB. Advances in the treatment of cutaneous leishmaniasis in the new world in the last ten years: a systematic literature review. Anais brasileiros de Dermatol. 2011;86(3):497\u2013506.","journal-title":"Anais brasileiros de Dermatol"},{"issue":"8","key":"4784_CR16","doi-asserted-by":"publisher","first-page":"e525","DOI":"10.1016\/j.ijid.2011.03.021","volume":"15","author":"TS Tiuman","year":"2011","unstructured":"Tiuman TS, Santos AO, Ueda-Nakamura T, Dias Filho BP, Nakamura CV. Recent advances in leishmaniasis treatment. Int J|Infect Dis. 2011;15(8):e525\u201332.","journal-title":"Int J|Infect Dis."},{"issue":"11","key":"4784_CR17","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.pt.2003.09.008","volume":"19","author":"SL Croft","year":"2003","unstructured":"Croft SL, Coombs GH. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 2003;19(11):502\u20138.","journal-title":"Trends Parasitol"},{"issue":"2","key":"4784_CR18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.exppara.2013.07.018","volume":"135","author":"E Kazemi-Rad","year":"2013","unstructured":"Kazemi-Rad E, Mohebali M, Khadem-Erfan MB, Saffari M, Raoofian R, Hajjaran H, et al. Identification of antimony resistance markers in Leishmania tropica field isolates through a cDNA-AFLP approach. Exp Parasitol. 2013;135(2):344\u20139.","journal-title":"Exp Parasitol"},{"issue":"1","key":"4784_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","volume":"19","author":"SL Croft","year":"2006","unstructured":"Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006;19(1):111\u201326.","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"4784_CR20","first-page":"166","volume":"120","author":"C Thakur","year":"2004","unstructured":"Thakur C, Narayan S, Ranjan A. Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India. Indian J Med Res. 2004;120(3):166.","journal-title":"Indian J Med Res"},{"issue":"5","key":"4784_CR21","doi-asserted-by":"publisher","first-page":"e162","DOI":"10.1371\/journal.pmed.0030162","volume":"3","author":"R Hadighi","year":"2006","unstructured":"Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M. Unresponsiveness to glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS medicine. 2006;3(5):e162.","journal-title":"PLoS medicine."},{"issue":"1","key":"4784_CR22","first-page":"19","volume":"10","author":"M Zarean","year":"2015","unstructured":"Zarean M, Maraghi S, Hajjaran H, Mohebali M, Feiz-Hadad MH, Assarehzadegan MA. Comparison of proteome profiling of two sensitive and resistant field Iranian isolates of Leishmania major to Glucantime\u00ae by 2-dimensional electrophoresis. Iran J Parasitol. 2015;10(1):19.","journal-title":"Iran J Parasitol."},{"issue":"1","key":"4784_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00436-012-2823-z","volume":"111","author":"D Kumar","year":"2012","unstructured":"Kumar D, Singh R, Bhandari V, Kulshrestha A, Negi NS, Salotra P. Biomarkers of antimony resistance: need for expression analysis of multiple genes to distinguish resistance phenotype in clinical isolates of Leishmania donovani. Parasitol Res. 2012;111(1):223\u201330.","journal-title":"Parasitol Res"},{"issue":"4","key":"4784_CR24","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1086\/318121","volume":"31","author":"S Sundar","year":"2000","unstructured":"Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis. 2000;31(4):1104\u20137.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4784_CR25","doi-asserted-by":"publisher","first-page":"e1463","DOI":"10.1371\/journal.pntd.0001463","volume":"6","author":"M Plourde","year":"2012","unstructured":"Plourde M, Coelho A, Keynan Y, Larios OE, Ndao M, Ruest A, et al. Genetic polymorphisms and drug susceptibility in four isolates of Leishmania tropica obtained from Canadian soldiers returning from Afghanistan. PLoS Negl Trop Dis. 2012;6(1):e1463.","journal-title":"PLoS Negl Trop Dis"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-019-4784-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13104-019-4784-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-019-4784-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T14:32:33Z","timestamp":1722177153000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-019-4784-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4784"],"URL":"https:\/\/doi.org\/10.1186\/s13104-019-4784-0","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"17 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study approved in Ethical Committee of Kerman University of Medical Sciences. The Ethical Approval Code is IR.KMU.REC.1397.267.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"803"}}